# US 2025/0375447 A1 · Treatment of cancer utilizing an identified adenosine fingerprint

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375447 A1
- Document ID: US20250375447A1
- Status: Published application
- Kind: A1
- Application number: 19/193,841
- Filed: 2025-04-29
- Published: 2025-12-11
- Earliest claimed: 2019-03-29
- Assignees: Arcus Biosciences, Inc.
- Applicants: Arcus Biosciences, Inc.
- Inventors: Amy Elizabeth Anderson; Devika Ashok; Daniel M. DiRenzo; Akshata R. Udyavar; Matthew J. Walters; Stephen W. Young
- Web page: https://patentgrep.com/patent/US20250375447A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods of treating a cancer in a subject having an established adenosine fingerprint. An established adenosine fingerprint includes assessing the blood concentration of one or more adenosine machinery proteins, assessing the enzymatic activity of one or more adenosine machinery proteins, and/or assessing the tumor expression level of adenosine machinery proteins. The methods disclosed herein include administering to said subjects a therapeutic agent selected from the group consisting of an agent targeting the extracellular production of adenosine, and an agent antagonizing the activation by adenosine of one of its receptors.

## Claims

### Claim at position 1

-78. (canceled)

### Claim 79

A method of inhibiting or suppressing a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an adenosine A2a receptor (A2aR) or adenosine A2b receptor (A2bR) antagonist,
wherein the cancer has an established adenosine fingerprint determined from a biopsy from the subject,
wherein the established adenosine fingerprint is an increase in the amount of CD73 as determined by immunostaining for CD73,
wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above a threshold value that is a CD73 staining of 1% or more of cancer cells in the biopsy or a measured value above an average value of CD73 immunostaining in biopsy samples from a population of subjects with the same type of cancer, and
wherein the adenosine A2a receptor (A2aR) or adenosine A2b receptor (A2bR) antagonist is Compound 2
or a pharmaceutically acceptable salt thereof.

### Claim 80 (depends on 79)

The method of claim 79, wherein the increase in the amount of CD73 as determined by immunostaining is calculated as positive staining area, percentage of positive staining cells, H-score, combined positive score, or tumor proportion score.

### Claim 81 (depends on 79)

The method of claim 79, wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above the average value of CD73 immunostaining in biopsy samples from a population of subjects with the same type of cancer.

### Claim 82 (depends on 79)

The method of claim 79, wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above a threshold value that is a CD73 staining of 1% or more of cancer cells in the biopsy.

### Claim 83 (depends on 79)

The method of claim 79, wherein the cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone, or the cancer is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, or testicular carcinoma.

### Claim 84 (depends on 79)

The method of claim 79, further comprising administering to the subject a PD1 inhibitor and/or a PD-L1 inhibitor.

### Claim 85 (depends on 85)

The method of claim 85, wherein the PD1 and/or PD-L1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, MEDI-0680, BGB-108, GB-226, PDR-001, mDX-400, SHR-1210, IBI-308, PF-06801591, atezolizumab, durvalumab, avelumab, BMS-936559, KD-033, CA-327, CA-170, ALN-PDL, TSR-042, and STI-1014.

### Claim 86 (depends on 79)

The method of claim 79, further comprising a chemotherapeutic agent, wherein the chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent.